Literature DB >> 3670125

Activation of the human complement cascade by bacterial cell walls, peptidoglycans, water-soluble peptidoglycan components, and synthetic muramylpeptides--studies on active components and structural requirements.

A Kawasaki1, H Takada, S Kotani, S Inai, K Nagaki, M Matsumoto, K Yokogawa, S Kawata, S Kusumoto, T Shiba.   

Abstract

Cell walls isolated from 29 strains of 24 gram-positive bacterial species, whose peptidoglycans belong to the group A type of Schleifer and Kandler's classification, with one exception (Arthrobacter sp.), were shown to activate the complement cascade in pooled fresh human serum mainly through the alternative pathway and partly through the classical one. The complement-activating effect of cell walls (5 species) possessing group B type peptidoglycan, except those of Corynebacterium insidiosum, was weaker than that of the walls with group A type peptidoglycan. Preparations of peptidoglycan isolated from cell walls of Staphylococcus aureus, Streptococcus pyogenes, and Lactobacillus plantarum also activated the alternative pathway of the complement cascade, but less effectively than the respective parent cell walls. A water-soluble "polymer" of peptidoglycan subunits (SEPS), which was prepared from Staphylococcus epidermidis peptidoglycans by treatment with a cross-bridge degrading endopeptidase, retained most of the complement-activating ability of the parent cell walls. A peptidoglycan "monomer," SEPS-M, which was obtained by hydrolysis of the glycan chain of SEPS with endo-N-acetylmuramidase to disaccharide units did not activate complement. In conformity with this finding, neither synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) nor MDP-L-Lys-D-Ala activated the complement cascade. Among several lipophilic derivatives of MDP, 6-O-(3-hydroxy-3-docosylhexacosanoyl)-MDP-L-Lys-D-Ala (BH48-MDP-L-Lys-D-Ala) and 6-O-(2-tetradecylhexadecanoyl)-MDP (B30-MDP) were shown to activate complement through the alternative as well as the classical pathway and exclusively through the classical pathway, respectively. The finding that a D-isoasparagine analog of B30-MDP caused the same effect as the parent molecule strongly suggests that the activation of complement by B30-MDP is different from that caused by cell wall peptidoglycans and a water-soluble "polymer" of peptidoglycan subunits.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3670125     DOI: 10.1111/j.1348-0421.1987.tb03117.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  6 in total

Review 1.  Carbohydrate-based immune adjuvants.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

2.  Role of peptidoglycan subtypes in the pathogenesis of bacterial cell wall arthritis.

Authors:  E Simelyte; M Rimpiläinen; X Zhang; P Toivanen
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

3.  Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry.

Authors:  Hui Chen; Michael C Schuster; Georgia Sfyroera; Brian V Geisbrecht; John D Lambris
Journal:  J Am Soc Mass Spectrom       Date:  2008-01       Impact factor: 3.109

4.  Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides.

Authors:  H Takada; Y Kawabata; S Kawata; S Kusumoto
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

5.  Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons.

Authors:  Ravi Shankar Keshari; Narcis Ioan Popescu; Robert Silasi; Girija Regmi; Cristina Lupu; Joe H Simmons; Alonso Ricardo; K Mark Coggeshall; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

6.  Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent.

Authors:  Carla J C de Haas; Karin Ellen Veldkamp; Andreas Peschel; Floor Weerkamp; Willem J B Van Wamel; Erik C J M Heezius; Miriam J J G Poppelier; Kok P M Van Kessel; Jos A G van Strijp
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.